sheaths can cause access-site complications. We aim to examine these complications. Methods:Data in 210 patients undergoing TAVR 2008-2014 were examined for peripheral access-site vascular complication (PVAC) using Valve Academic Research Consortium (VARC) 2 criteria. Results: Seventeen (8.1%) patients suffered a PVAC (13 major, 4 minor). Of the 17 patients, 2 (11.7%) required thrombin injection, 4 (23.5%) required surgical intervention, 5 (29.4%) required stent implantation and 1 (5.9%) required angioplasty. Five (29.4%) patients were managed conservatively. Comparing thosewith andwithout PVAC, thereweremore females (76.5% vs. 49.7%, p 2 (11.8%vs. 13.5%) p≥0.28. Of the 6 patients treated percutaneously, 1 died 7 days postprocedure from neurological complications and 1 patient had an intentional occlusion of their superficial femoral artery but no associated morbidity. All other patients made a full recovery with no medium-term sequelae. Conclusion: TAVR peripheral vascular access complications are infrequent and most subjects make a full recovery. Importantly, peripheral stenting alone has not caused any medium-term morbidity in patients. Further research into this area is needed to evaluate benefits of stenting over surgical repair for peripheral vascular complications of TAVR.